RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) Stock Price & Analysis
RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) — price $8.16 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.09B.
Educational signal · not a buy or sell recommendation · How to read this
RHÖN-KLINIKUM Aktiengesellschaft · RKAGY
RHÖN-KLINIKUM Aktiengesellschaft operates as a healthcare service provider in Germany, offering in-patient, semi-patient, and outpatient services. The company manages eight hospitals across five medical sites, providing a range of treatments and rehabilitation programs.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.16 | |
| Change on the day | 0.00% | |
| Market capitalisation | $1.09B | |
| Price / earnings (trailing) | 22.97 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for RHÖN-KLINIKUM Aktiengesellschaft (RKAGY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is RHÖN-KLINIKUM Aktiengesellschaft (RKAGY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) is the company analyzed here. It employs 19,244 people. In Q3 FY2026 it reported revenue of €526M and net income of €10M. The market values it at $1.09B.
What do the latest results show for RHÖN-KLINIKUM Aktiengesellschaft (RKAGY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €526M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €526M | €10M | €0.07 (diluted) |
| Q2 FY2026 | €427M | €9M | €0.07 (diluted) |
| Q1 FY2026 | €443M | €13M | €0.10 (diluted) |
| Q4 FY2025 | €438M | €10M | €0.07 (diluted) |
What are the financial strengths and risks for RHÖN-KLINIKUM Aktiengesellschaft (RKAGY)?
Short answer · as of
The distress and quality screens read Altman Z 2.76 · Piotroski F 6. Trailing ratios: ROE 3.2% · ROA 2.3% · current ratio 2.69 · earnings yield 4.5%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RKAGY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RKAGY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: RKAGY Stock
These answers are editorial: 1 of these 8 answers is drawn from the RKAGY research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RKAGY a good stock to buy?
Stock Expert AI does not rate RKAGY buy, sell or hold. RHÖN-KLINIKUM Aktiengesellschaft has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RKAGY stock price today?
The last price recorded for RHÖN-KLINIKUM Aktiengesellschaft (RKAGY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for RKAGY?
The main risks for RHÖN-KLINIKUM AG include regulatory changes in the German healthcare system, which could impact reimbursement rates and operational costs. Increased competition from other healthcare providers may erode market share. Rising costs of medical equipment and supplies could squeeze profit margins.
What are the key factors to evaluate for RKAGY?
Evaluate RKAGY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The German healthcare market is consolidating, with smaller clinics being acquired by larger hospital groups. Not financial advice.
How frequently does RKAGY data refresh on this page?
RKAGY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RKAGY's recent stock price performance?
RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the German healthcare market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RKAGY overvalued or undervalued right now?
The trailing P/E of RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RKAGY before investing?
Before investing in RHÖN-KLINIKUM Aktiengesellschaft (RKAGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 10 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com